Unnatural Products
A biotech company using AI to develop next generation molecularly targeted therapeutics.
In December 2023, the Californian company announced $32 million in Series A funding, led by Merck Global Health Innovation Fund (MGHIF) and TechBio-focused ARTIS Ventures. A month later, it announced a collaboration with Merck to apply Unnatural's technology to design and develop macrocyclic candidates against an oncology therapeutic target.
Latest Unnatural Products News & Features
24 January 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze